
|Articles|May 23, 2018
The Fundamental Disconnect Between Pharma and Technology
Author(s)Michelle Maskaly
Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system.
Advertisement
Otsuka Pharmaceutical’s President and CEO of Development and Commercialization William Carson explains the initial growing pains the company went through with their technology company partner in the early development stages of the first U.S. FDA approved digital medicine system, Abilify Mycite.
His interview was recorded during the May 2018 Financial Times Live ‘s US Healthcare & Life Sciences Summit in New York City.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
3
Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D
4
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
5




